Transgene

Transgene Stock-Based Compensation

The Stock-Based Compensation (SBC) of Transgene (TNG.PA) as of Nov 19, 2026 is 568,000.00 EUR. In the previous year, Stock-Based Compensation (SBC) was 290,000.00 EUR — a change of 95.86% (higher).

Stock-Based Compensation

568,000.00EUR

YoY

95.86%

Last updated:

Stock-Based Compensation (SBC) of Transgene is 2024 568,000.00 EUR. Stock-Based Compensation (SBC) of Transgene was 2023 290,000.00 EUR. It decreases by 95.86% higher compared to the previous year.

The Transgene Stock-Based Compensation history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Stock-Based Compensation
Date
Stock-Based Compensation
Jan 1, 2017
500,000.00 EUR
Jan 1, 2018
500,000.00 EUR
Jan 1, 2019
1.30 M EUR
Jan 1, 2020
1.74 M EUR
Jan 1, 2021
3.00 M EUR
Jan 1, 2022
2.68 M EUR
Jan 1, 2023
290,000.00 EUR
Jan 1, 2024
568,000.00 EUR
The Transgene Stock-Based Compensation history
YEARStock-Based CompensationYoY
568,000.00EUR+95.86%
290,000.00EUR-89.16%
2.68 MEUR-10.89%
3.00 MEUR+72.13%
1.74 MEUR+34.15%
1.30 MEUR+160.00%
500,000.00EUR0.00%
500,000.00EUR+150.00%
200,000.00EUR-50.00%
400,000.00EUR-42.86%
700,000.00EUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Transgene Stock analysis

What does Transgene do? Transgene SA is a French biotechnology company specializing in the development and production of therapeutics, with a focus on cancer medications. It has a strong patent portfolio in the field of viral vectors, which are used for targeted gene therapy. The company's main areas of operation are clinical trials, research, and production. Transgene has research and production facilities in Strasbourg and Lyon, with over 100 employees. It has established partnerships with pharmaceutical companies, including Takeda Pharmaceuticals, for the development and marketing of therapeutics. Its flagship product, OncoVir-1®, is an immunomodulator that stimulates the immune system to fight tumor cells. Another promising product is TG4010, a therapeutic vaccine for non-small cell lung carcinoma. Transgene is an emerging company with a promising portfolio of cancer therapeutics, leveraging its expertise in viral vectors and collaborating closely with industry partners to expedite the development of marketable products. Transgene is expected to play a significant role in the development of new and innovative cancer treatments. Transgene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Transgene stock

Stock-Based Compensation (SBC) of Transgene is 568,000.00 EUR in 2024.

Stock-Based Compensation (SBC) of Transgene changed from 290,000.00 EUR to 568,000.00 EUR, representing a 95.86% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Stock-Based Compensation (SBC) Transgene since 2006 – with annual values, charts, and detailed analysis.

Stock-based compensation is a non-cash expense representing equity awards to employees. High SBC can dilute existing shareholders and inflate reported cash flow.

Stock-Based Compensation (SBC)'s EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Stock-Based Compensation (SBC)'s Transgene historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Transgene

All Key Metrics — Transgene